AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02587962
Drug: Birinapant
RxNorm normalized name: Birinapant
DrugBank: Birinapant (DB11782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
Trial: NCT02587962
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
Trial: NCT01683032
Drug: MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a capsule containing 20 mg
Trial: NCT00487669
Drug: paclitaxel poliglumex, pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
Trial: NCT01850420
Drug: IMC-1
RxNorm normalized name: IMC-1C11
DrugBank: IMC-1C11 (DB06101)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03005522
Drug: oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
Trial: NCT00626223
Drug: 5-MTHF (5-methyltetrahydrofolate)
RxNorm normalized name: (6S)-5-MTHF
DrugBank: Levomefolic acid (DB11256)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous at the end of each hemodialysis session
Trial: NCT01767428
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg immediate release paracetamol formulations
Trial: NCT01423318
Drug: lebrikizumab
RxNorm normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-level cohorts receiving single subcutaneous dose
Trial: NCT01895296
Drug: Pasireotide
RxNorm normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: somatostatin analogue pasireotide
Trial: NCT02667275
Drug: A-101 Solution
RxNorm normalized name: OXT-101
DrugBank: P-BCMA-101 (DB17371)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04483674
Drug: 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL
Trial: NCT01756040
Drug: Lactulose -rhamnose solution
RxNorm normalized name: rhamnose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
Trial: NCT01414881
Drug: mipomersen
RxNorm normalized name: Mipomersen
DrugBank: Mipomersen (DB05528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mipomersen 200mg subcutaneously (SC) once weekly
Trial: NCT02593162
Drug: Faldaprevir
RxNorm normalized name: Faldaprevir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02593162
Drug: TD-6450
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02593162
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03895684
Drug: SP-2577 Seclidemstat
RxNorm normalized name: SPS
DrugBank: Seclidemstat (DB17117)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation and dose expansion of SP-2577.
Trial: NCT00185705
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03960970
Drug: Mefoxin 2g
RxNorm normalized name: Mefoxin 2g Powder for Injection
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Prophylaxis
Trial: NCT03830606
Drug: Nab-paclitaxel,S-1
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
Trial: NCT03182322
Drug: intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
Trial: NCT03870490
Drug: VNRX-5133 + cefepime
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion (3 doses)
Trial: NCT02069665
Drug: Ribavirin Injection
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
Trial: NCT02069665
Drug: Guaifenesin Syrup
RxNorm normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
Trial: NCT02069665
Drug: salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: taken under prescription
Trial: NCT04513379
Drug: Efavirenz 600mg
RxNorm normalized name: EFAVIRENZ 600MG TAB
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EFV 600 mg per day given orally
Trial: NCT04513379
Drug: Efavirenz 400mg
RxNorm normalized name: EFAVIRENZ 400MG/LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets of EFV 200 mg per day given orally
Trial: NCT02946125
Drug: Phenylephrine 2.5% Eyedrop
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
Trial: NCT02946125
Drug: Phenylephrine 10% Eyedrop
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
Trial: NCT02305758
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
Trial: NCT02305758
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
Trial: NCT00191880
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01155765
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 10 mg/day for 15 days
Trial: NCT00130702
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gefitinib (Iressa) at a dose of 750 mg, once per day
Trial: NCT00824265
Drug: OFC Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
Trial: NCT01155765
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 150 mg/day for 15 days
Trial: NCT01110616
Drug: Comparator: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam, 2 mg (2 x 1 mg tablet), orally
Trial: NCT00280371
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001520
Drug: neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01688596
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
Trial: NCT00457353
Drug: Bacillus Clausii
RxNorm normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 5 days
Trial: NCT00549939
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight
Trial: NCT01172197
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Femoral bolus 150μM followed by femoral infusion 400μM
Trial: NCT01172197
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus and infusion
Trial: NCT01767454
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
Trial: NCT01767454
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
Trial: NCT01767454
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
Trial: NCT01360554
Drug: Dacomitinib (PF-00299804)
RxNorm normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
Trial: NCT01360554
Drug: Active Comparator (erlotinib)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
Trial: NCT00051675
Drug: ING-1(heMAb)
RxNorm normalized name: ING-1
DrugBank: ING-1 (DB05831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04223843
Drug: Tiotropium + olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Inhalation
Trial: NCT02678338
Drug: Hu5F9-G4
RxNorm normalized name: Anti-cd47 monoclonal antibody hu5f9-g4
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02428855
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01312038
Drug: Simethicone
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 125 mg chewable tablet
Trial: NCT00757874
Drug: Tacrolimus cream
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 g per day at bed time for 3 months or less.
Trial: NCT00757874
Drug: Clobetasol cream
RxNorm normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 gram each day at bed time during 3 months or less.
Trial: NCT01442194
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01848340
Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744B
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A white to slightly colored nonsterile crystalline powder for oral solution
Trial: NCT01930864
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin up to 2500mg/d
Trial: NCT01930864
Drug: irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 350 mg/m² IV q21d
Trial: NCT04312880
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV and topical form of TXA will be administered to patients in the respective groups.
Trial: NCT02492568
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03093883
Drug: Venofer
RxNorm normalized name: Venofer
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Trial: NCT00032123
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00834171
Drug: Loteprednol etabonate ophthalmic suspension 0.5%
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
Trial: NCT01450995
Drug: Treximet
RxNorm normalized name: Treximet
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
Trial: NCT03488186
Drug: Lansoprazole Capsules
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
Trial: NCT01295372
Drug: Zicronapine
RxNorm normalized name: Zicronapine
DrugBank: Zicronapine (DB12188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day; orally
Trial: NCT01295372
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg/day; orally
Trial: NCT01860404
Drug: Branched Chain Amino Acids
RxNorm normalized name: Branched Chain Amino Acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The three BCAA's will be combined together and dissolved in a flavored solution.
Trial: NCT01027143
Drug: Omega-3 Fatty Acid
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil: 3(age 12-25) matched softgel caps twice daily
Trial: NCT01497652
Drug: Rasagiline/Placebo
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will receive placebo pills each day for the entire 14 weeks.
Trial: NCT01497652
Drug: Rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mg for two weeks, then 1 mg for 12 weeks.
Trial: NCT00081952
Drug: L-norleucine
RxNorm normalized name: L-NORLEUCINE
DrugBank: Norleucine (DB15458)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00038675
Drug: Imatinib Mesylate (Gleevec)
RxNorm normalized name: imatinib Oral Tablet [Gleevec]
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
Trial: NCT03601637
Drug: LUM
RxNorm normalized name: Alum
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination (FDC) granules (LUM/IVA).
Trial: NCT03601637
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDC granules (LUM/IVA).
Trial: NCT03931161
Drug: Evolocumab Auto-Injector [Repatha]
RxNorm normalized name: evolocumab Auto-Injector [Repatha]
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Auto-Injector, 140 mg every two weeks.
Trial: NCT01248247
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth each day of a 28 day cycle.
Trial: NCT01248247
Drug: MK-2206
RxNorm normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg by mouth every week of a 28 day cycle.
Trial: NCT01248247
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg by mouth twice a day for a 28 day cycle.
Trial: NCT01248247
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth daily of a 28 day cycle.
Trial: NCT01248247
Drug: MK-2206
RxNorm normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg by mouth every week of a 28 day cycle.
Trial: NCT03149653
Drug: ClinOleic (baseline)
RxNorm normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Trial: NCT03149653
Drug: ClinOleic + Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Trial: NCT03149653
Drug: Lipoplus (baseline)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Trial: NCT03149653
Drug: Lipoplus + Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Trial: NCT03149653
Drug: SMOFlipid (baseline)
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Trial: NCT03149653
Drug: SMOFlipid + Omegaven
RxNorm normalized name: Omegaven
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Trial: NCT03726866
Drug: Sequence 2
RxNorm normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: D326, D337 or CKD-828 for 9 days
Trial: NCT03726866
Drug: Sequence 3
RxNorm normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: D326, D337 or CKD-828 for 9 days
Trial: NCT03726866
Drug: Sequence 4
RxNorm normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: D326, D337 or CKD-828 for 9 days
Trial: NCT03726866
Drug: Sequence 6
RxNorm normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: D326, D337 or CKD-828 for 9 days
Trial: NCT03081442
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
Trial: NCT01511939
Drug: Pennsaid
RxNorm normalized name: Pennsaid
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
Trial: NCT03203447
Drug: suprachoroidal CLS-TA
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprachoroidal injection of CLS-TA
Trial: NCT03203447
Drug: suprachoroidal sham
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham suprachoroidal procedure